NewAmsterdam Total Liab from 2010 to 2025
| NAMSW Stock | 12.51 0.24 1.96% |
Total Liabilities | First Reported 2010-12-31 | Previous Quarter 107.1 M | Current Value 112.5 M | Quarterly Volatility 34.2 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Total Liab |
Latest NewAmsterdam Pharma's Total Liab Growth Pattern
Below is the plot of the Total Liab of NewAmsterdam Pharma over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. NewAmsterdam Pharma's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
NewAmsterdam Total Liab Regression Statistics
| Arithmetic Mean | 29,765,062 | |
| Geometric Mean | 19,679,350 | |
| Coefficient Of Variation | 114.80 | |
| Mean Deviation | 25,787,719 | |
| Median | 12,808,000 | |
| Standard Deviation | 34,171,632 | |
| Sample Variance | 1167.7T | |
| Range | 102.5M | |
| R-Value | 0.72 | |
| Mean Square Error | 602.4T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 5,168,381 | |
| Total Sum of Squares | 17515.5T |
NewAmsterdam Total Liab History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 107.1 M | 112.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.